Company intelligence / Profile preview

Gen.Orph

Paris, France

Ownership: Private
Development stage: Other

Overview

Gen.Orph is a French pharmaceutical company dedicated to the development and commercialization of treatments for rare and orphan diseases. The company's primary focus is on nephropathic cystinosis, a rare genetic metabolic disorder, for which it provides specialized therapeutic solutions. Gen.Orph is best known for its product Cystadrops, an ophthalmic solution designed to treat corneal cystine crystals. The company operates primarily in the European market, ensuring access to essential medications for patient populations with high unmet medical needs.

Therapeutic areas: NephrologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Recordati Rare Diseases

Beyond the preview

Go deeper on Gen.Orph.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gen.Orph.

Explore the full profile